Alpha-synuclein and iron: two keys unlocking Parkinson's disease

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Parkinson's disease (PD) therapies primarily offer symptomatic relief, especially for motor deficits in early stages.
• Current treatments do not address the underlying neurodegenerative processes due to incomplete understanding of disease mechanisms.
• Two key pathological mechanisms in PD are alpha-synuclein aggregation and disrupted iron homeostasis.

Purpose of the Study:

• To review the intricate interaction between alpha-synuclein pathology and iron homeostasis dysfunction in PD.
• To summarize current translational therapeutic strategies targeting these mechanisms, including iron chelation and alpha-synuclein modification.
• To discuss the potential and challenges of developing disease-modifying pharmacological treatments for PD.

Main Methods:

• Literature review focusing on alpha-synuclein pathology in Parkinson's disease.
• Analysis of studies investigating iron homeostasis and its role in neurodegeneration.
• Examination of current preclinical and clinical research on iron chelation and alpha-synuclein-targeting agents for PD.

Main Results:

• Alpha-synuclein aggregation and iron dysregulation are interconnected and pivotal in PD pathogenesis.
• Iron chelation and strategies to modify alpha-synuclein pathology show promise as therapeutic avenues.
• Understanding the interplay between these mechanisms is crucial for developing effective disease-modifying treatments.

Conclusions:

• Targeting alpha-synuclein pathology and iron homeostasis represents a promising strategy for disease modification in Parkinson's disease.
• Further research is needed to overcome challenges in translating these findings into effective pharmacological therapies.
• Combined approaches addressing both mechanisms may offer enhanced therapeutic benefits for PD patients.